title: Generation of CD8+ T cell-mediated immunity against idiotype-negative lymphoma escapees.
abstract: We investigated the ability of CpG-oligodeoxynucleotide to generate an anti-tumor CD8+ T-cell immune response and to synergize with passive antibody therapy. For these studies, we generated an antibody against the idiotype on the A20 B-cell lymphoma line. This antibody caused the regression of established tumors, but ultimately the tumors relapsed. The escaping surface IgG-negative tumor cells were resistant to both antibody-dependent cellular cytotoxicity and signaling-induced cell death. Addition of intratumoral CpG to antibody therapy cured large established tumors and prevented the occurrence of tumor escapees. The failure of the combination therapy in mice deficient for CD8+ T cells demonstrates the critical role of CD8+ T cells in tumor eradication. When mice were inoculated with 2 tumors and treated systemically with antibody followed by intratumoral CpG in just one tumor, both tumors regressed, indicating that a systemic immune response was generated. Although antibody therapy can eliminate tumor cells bearing the target antigen, it frequently selects for antigen loss variants. However, when a poly-specific T-cell response was generated against the tumor by intratumoral CpG, even large established tumors were cured. Such an immune response can prevent the emergence of antibody selected tumor escapees and provide long-lasting tumor protection.
authors.affiliation: Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
authors.forename: Bindu
authors.initials: B
authors.lastname: Varghese
authors.forename: Adam
authors.initials: A
authors.lastname: Widman
authors.forename: James
authors.initials: J
authors.lastname: Do
authors.forename: Behnaz
authors.initials: B
authors.lastname: Taidi
authors.forename: Debra K
authors.initials: DK
authors.lastname: Czerwinski
authors.forename: John
authors.initials: J
authors.lastname: Timmerman
authors.forename: Shoshana
authors.initials: S
authors.lastname: Levy
authors.forename: Ronald
authors.initials: R
authors.lastname: Levy
mesh_terms: D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology* / Q000627:therapeutic use; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology; D005434:Flow Cytometry; D007167:Immunotherapy / Q000379:methods*; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D018345:Mice, Knockout; D009838:Oligodeoxyribonucleotides / Q000276:immunology*; D019139:Tumor Escape / Q000276:immunology*
chemical_list: D000888:Antibodies, Anti-Idiotypic; C408982:CPG-oligonucleotide; D019496:Cancer Vaccines; D009838:Oligodeoxyribonucleotides